Detalles de la búsqueda
1.
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Br J Dermatol
; 188(6): 740-748, 2023 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36994947
2.
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial.
J Am Acad Dermatol
; 85(2): 360-368, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33253833
3.
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).
J Drugs Dermatol
; 20(8): 880-887, 2021 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34397207
4.
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
Br J Dermatol
; 190(2): 289-291, 2024 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37939793
5.
Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials.
J Dermatolog Treat
; 35(1): 2329240, 2024 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38679419
6.
Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis.
Adv Ther
; 41(4): 1512-1525, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38363461
7.
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials.
J Dermatolog Treat
; 35(1): 2324833, 2024 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38735650
8.
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
JAMA Dermatol
; 159(2): 182-191, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36630140
9.
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
Am J Clin Dermatol
; 24(4): 595-607, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37195407
10.
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
Dermatol Ther (Heidelb)
; 10(3): 431-447, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32200512
Resultados
1 -
10
de 10
1
Próxima >
>>